Repository logo
 

The COVID-19 pandemic and ANCA-associated vasculitis - reports from the EUVAS meeting and EUVAS education forum.

Simple item page
cam.issuedOnline2021-10-28
dc.contributor.authorKronbichler, Andreas
dc.contributor.authorGeetha, Duvuru
dc.contributor.authorSmith, Rona M
dc.contributor.authorEgan, Allyson C
dc.contributor.authorBajema, Ingeborg M
dc.contributor.authorSchönermarck, Ulf
dc.contributor.authorMahr, Alfred
dc.contributor.authorAnders, Hans-Joachim
dc.contributor.authorBruchfeld, Annette
dc.contributor.authorCid, Maria C
dc.contributor.authorJayne, David RW
dc.contributor.orcidKronbichler, Andreas [0000-0002-2945-2946]
dc.contributor.orcidJayne, David [0000-0002-1712-0637]
dc.date.accessioned2022-01-06T12:54:20Z
dc.date.available2022-01-06T12:54:20Z
dc.date.issued2021-12
dc.date.updated2022-01-06T12:54:19Z
dc.description.abstractThe Coronavirus Disease 2019 (COVID-19) pandemic influenced the management of patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. A paucity of data exists on outcome of patients with vasculitis following COVID-19, but mortality is higher than in the general population and comparable to patients undergoing haemodialysis or kidney transplant recipients (reported mortality rates of 20-25%). Delays in diagnosis have been reported, which are associated with sequelae such as dialysis-dependency. Management of ANCA-associated vasculitis has not changed with the aim to suppress disease activity and reduce burden of disease. The use of rituximab, an important and widely used agent, is associated with a more severe hospital course of COVID-19 and absence of antibodies following severe acute respiratory syndrome (SARS)-CoV-2 infections, which prone patients to re-infection. Reports on vaccine antibody response are scarce at the moment, but preliminary findings point towards an impaired immune response, especially when patients receive rituximab as part of their treatment. Seropositivity was reported in less than 20% of patients when rituximab was administered within the prior six months, and the antibody response correlated with CD19+ B-cell repopulation. A delay in maintenance doses, if disease activity allows, has been suggested using a CD19+ B-cell guided strategy. Other immunosuppressive measures, which are used in ANCA-associated vasculitis, also impair humoral and cellular vaccine responses. Regular measurements of vaccine response or a healthcare-policy time-based strategy are indicated to provide additional doses ("booster") of COVID-19 vaccines. This review summarizes a recent educational forum and a recent virtual meeting of the European Vasculitis Society (EUVAS) focusing on COVID-19.
dc.identifier.doi10.17863/CAM.79641
dc.identifier.eissn1873-0183
dc.identifier.issn1568-9972
dc.identifier.otherPMC8552556
dc.identifier.other34718165
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/332195
dc.languageeng
dc.language.isoeng
dc.publisherElsevier BV
dc.publisher.urlhttp://dx.doi.org/10.1016/j.autrev.2021.102986
dc.sourceessn: 1873-0183
dc.sourcenlmid: 101128967
dc.subjectAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
dc.subjectAntibodies, Antineutrophil Cytoplasmic
dc.subjectCOVID-19
dc.subjectCOVID-19 Vaccines
dc.subjectHumans
dc.subjectPandemics
dc.subjectRituximab
dc.subjectSARS-CoV-2
dc.titleThe COVID-19 pandemic and ANCA-associated vasculitis - reports from the EUVAS meeting and EUVAS education forum.
dc.typeArticle
dcterms.dateAccepted2021-07-24
prism.issueIdentifier12
prism.publicationNameAutoimmun Rev
prism.volume20
rioxxterms.versionVoR
rioxxterms.versionofrecord10.1016/j.autrev.2021.102986

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
article.pdf
Size:
528.41 KB
Format:
Adobe Portable Document Format
Description:
Published version
Download

Collections

Jisc Publications Router